» Articles » PMID: 24397693

The Application of Multiple Reaction Monitoring and Multi-analyte Profiling to HDL Proteins

Overview
Publisher Biomed Central
Date 2014 Jan 9
PMID 24397693
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Background: HDL carries a rich protein cargo and examining HDL protein composition promises to improve our understanding of its functions. Conventional mass spectrometry methods can be lengthy and difficult to extend to large populations. In addition, without prior enrichment of the sample, the ability of these methods to detect low abundance proteins is limited. Our objective was to develop a high-throughput approach to examine HDL protein composition applicable to diabetes and cardiovascular disease (CVD).

Methods: We optimized two multiplexed assays to examine HDL proteins using a quantitative immunoassay (Multi-Analyte Profiling- MAP) and mass spectrometric-based quantitative proteomics (Multiple Reaction Monitoring-MRM). We screened HDL proteins using human xMAP (90 protein panel) and MRM (56 protein panel). We extended the application of these two methods to HDL isolated from a group of participants with diabetes and prior cardiovascular events and a group of non-diabetic controls.

Results: We were able to quantitate 69 HDL proteins using MAP and 32 proteins using MRM. For several common proteins, the use of MRM and MAP was highly correlated (p < 0.01). Using MAP, several low abundance proteins implicated in atherosclerosis and inflammation were found on HDL. On the other hand, MRM allowed the examination of several HDL proteins not available by MAP.

Conclusions: MAP and MRM offer a sensitive and high-throughput approach to examine changes in HDL proteins in diabetes and CVD. This approach can be used to measure the presented HDL proteins in large clinical studies.

Citing Articles

Advances in Mass Spectrometry-Based Blood Metabolomics Profiling for Non-Cancer Diseases: A Comprehensive Review.

Demicheva E, Dordiuk V, Polanco Espino F, Ushenin K, Aboushanab S, Shevyrin V Metabolites. 2024; 14(1).

PMID: 38248857 PMC: 10820779. DOI: 10.3390/metabo14010054.


Extracellular Vesicles as Possible Plasma Markers and Mediators in Patients with Sepsis-Associated Delirium-A Pilot Study.

Plaschke K, Brenner T, Fiedler M, Holle T, von der Forst M, Wolf R Int J Mol Sci. 2023; 24(21).

PMID: 37958765 PMC: 10649316. DOI: 10.3390/ijms242115781.


Searching for Atherosclerosis Biomarkers by Proteomics: A Focus on Lesion Pathogenesis and Vulnerability.

Nieddu G, Formato M, Lepedda A Int J Mol Sci. 2023; 24(20).

PMID: 37894856 PMC: 10607641. DOI: 10.3390/ijms242015175.


Plasma high-density lipoprotein cargo is altered in Alzheimer's disease and is associated with regional brain volume.

Pedrini S, Doecke J, Hone E, Wang P, Thota R, Bush A J Neurochem. 2022; 163(1):53-67.

PMID: 36000528 PMC: 9804612. DOI: 10.1111/jnc.15681.


Deepening our understanding of HDL proteome.

Ronsein G, Vaisar T Expert Rev Proteomics. 2019; 16(9):749-760.

PMID: 31382838 PMC: 6802954. DOI: 10.1080/14789450.2019.1650645.


References
1.
Alwaili K, Bailey D, Awan Z, Bailey S, Ruel I, Hafiane A . The HDL proteome in acute coronary syndromes shifts to an inflammatory profile. Biochim Biophys Acta. 2011; 1821(3):405-15. DOI: 10.1016/j.bbalip.2011.07.013. View

2.
Nissen S, Tardif J, Nicholls S, Revkin J, Shear C, Duggan W . Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med. 2007; 356(13):1304-16. DOI: 10.1056/NEJMoa070635. View

3.
Schwartz G, Olsson A, Abt M, Ballantyne C, Barter P, Brumm J . Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012; 367(22):2089-99. DOI: 10.1056/NEJMoa1206797. View

4.
Arellano-Garcia M, Hu S, Wang J, Henson B, Zhou H, Chia D . Multiplexed immunobead-based assay for detection of oral cancer protein biomarkers in saliva. Oral Dis. 2009; 14(8):705-12. PMC: 2675698. DOI: 10.1111/j.1601-0825.2008.01488.x. View

5.
Anderson L, Hunter C . Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol Cell Proteomics. 2005; 5(4):573-88. DOI: 10.1074/mcp.M500331-MCP200. View